Piper Jaffray raises its price target on shares of Clovis Oncology (CLVS) just slightly from $36...

|About: Clovis Oncology (CLVS)|By:, SA News Editor

Piper Jaffray raises its price target on shares of Clovis Oncology (CLVS) just slightly from $36 to $100 (rating understandably lifted to Overweight from Neutral). Piper cites the CO-1686 data delivered at ASCO (previous). Shares +6.7% premarket and +93% since last week. (Also: SA contributor Brian Wilson's analysis of CO-1686)